Breast cancer: review of platinum-based cooperative group trials.
Platinum-based therapy has not traditionally played a significant clinical role in breast cancer in the metastatic, adjuvant, or neoadjuvant settings. Recent clinical studies, however, suggest that regimens of taxane/platinum/trastuzumab are effective option for first-line treatment of HER2-overexpressing metastatic disease, and that docetaxel/carboplatin is viable in first-line treatment of HER2-negative metastatic disease, as well as in neoadjuvant therapy of locally advanced breast cancer. Further evaluation of platinum-based regimens in large multicenter studies is warranted, and several such studies are currently in progress.